Daily Stock Opinions and Ratings

Opinions

Robert McWhirter Xillix Technologies Corp XLX-T DON'T BUY Apr 14, 2005

Did a financing and have some cash. Earnings estimates are for losses, $0.06 in 2005 and $0.02 in 2006. Estimates have been shaved down by about 10% in the last 90 days. Next earnings are due to be reported in 2 weeks. Great product, but still waiting for approval.

Robert McWhirter

Unlock Rating

$0.640

Stock price when the opinion was issued

medical services

It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

Get Signals Create your Watchlist

You might be interested:

BUY ON WEAKNESS

Sold his position for tax loss reasons in December. Would like to get back in at around $0.70/0.75. A terrific company. Likes their technology. If they get FDA approval, he would expect a price of $1.85/2.00 in 12/24 months.

WAIT

Interesting technology. They use white light, which is the conventional lighting, for looking inside the body, but also their proprietory flourescent lighting. The challenge is that the company is expected to burn a bunch of cash. Will wait for the sales to start and earnings start to turn.

HOLD

Hoping to get the FDA pre-market approval very soon and will be able to offer their flourescent device for early lung cancer detection. Interesting speculation.

BUY

Have a product for finding colon/lung cancer. The innovation in terms of product will be adopted by the industry.

TRADE

Waiting for the FDA approval and are fairly confidant they are going to get it. Just signed a marketing agreement with Conmed (CNMD-Q) which is an expert on high tech medical equipment. These 2 things should be a great impetus to put this company considerably higher.

WAIT

Have the FDA approval. The challenge in the recent quarter is that sales have been almost non-existant. Now ramping up their sales force which will be an increase in expenses. An excellent product, but a "wait and see" stock. Earnings may take a year, if not longer.

DON'T BUY

Has interesting technology that uses flourescent lighting to look inside the lungs re: early stage cancer. Ranks 678 out of 700 in the database, the bottom 10%. The market is waiting for sales to appear.

DON'T BUY

Have got approval from FDA. Estimates have gone down the last 90 days because they hired a large sales staff, but sales are not appearing as quickly as hoped. Earnings are expected to get better for Dec/06, but are still negative going from -$0.08 to -$0.05. Looking out to ’07, they are expecting to earn $0.01.

DON'T BUY

Small market cap of $15 million. Sales have not been as good as expected. Expected loss of $.04 in earnings in 2007.

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : hello@stockchase.com.

Robert McWhirter Xillix Technologies Corp XLX-T DON'T BUY Apr 14, 2005

You might be interested:

Xillix Technologies Corp(XLX-T)

Xillix Technologies Corp(XLX-T)

Xillix Technologies Corp(XLX-T)

Xillix Technologies Corp(XLX-T)

Xillix Technologies Corp(XLX-T)

Xillix Technologies Corp(XLX-T)

Xillix Technologies Corp(XLX-T)

Xillix Technologies Corp(XLX-T)

Xillix Technologies Corp(XLX-T)

Latest Buy Signals

Today's Top Picks

Popular Articles

Latest Sell Signals

Most Recent Experts

Bruce Murray

The Panic-Proof Portfolio (Stockchase Research)

The Weekly Buzzing Stocks by Billy Kawasaki

Chris Blumas

Stockchase Insights